In cancer, dysregulation of the cell cycle results in rapid and uncontrolled proliferation of cancer cells, as well as resistance to treatment, making it an attractive target for anticancer agents.57,58 First generation CDK inhibitors, such as roscotovine and flavopiridol, were generally pan-CDK inhibitors, and CDK2 was a common target across the class. This evidence concerns the gene CDK2 and cancer.